Human granulocytic anaplasmosis
|Human granulocytic anaplasmosis|
|Classification and external resources|
|eMedicine||med/3391 ped/655 emerg/159|
Human granulocytic anaplasmosis (HGA) (previously known as Human granulocytic ehrlichiosis, or HGE ) is an infectious disease caused by Anaplasma phagocytophilum, an obligate intracellular bacterium that is typically transmitted to humans by at least three kinds of ticks, Ixodes scapularis, Ixodes pacificus, and Dermacentor variabilis. These ticks also transmit Lyme disease and other tick borne diseases.
The first outbreak of Human Granulocytic Anaplasmosis (HGA) in the United States was in a patient in early 1990 in Wisconsin. He was kept in the hospital in Minnesota for testing, but died without a diagnosis. Over the next couple of years, many people within the same area of Wisconsin and Minnesota had come down with the same symptoms. It was discovered in 1994 that it was Human Granulocytic Ehrlichiosis (HGE), later to be known as HGA.
Ecology and epidemiology
A. phagocytophilum is transmitted to humans by Ixodes ticks. These ticks are found in the US, Europe, and Asia. In the US, I. scapularis is the tick vector in the East and Midwest states, and I. pacificus in the Pacific Northwest. In Europe, the I. ricinus is the main tick vector, and I. persulcatus is the currently known tick vector in Asia.
The major mammalian reservoir for A. phagocytophilum in the eastern United States is the white-footed mouse, Peromyscus leucopus. Although white-tailed deer and other small mammals harbor A. phagocytophilum, evidence suggests that they are not a reservoir for the strains that cause HGA. A tick that has a blood meal from and infected reservoir become infected themselves. If an infected tick then latches onto a human the disease is then transmitted to the human.
A tick that has a blood meal from an infected reservoir becomes infected themselves. If an infected tick then latches onto a human the disease is transmitted to the human host and A. phagocytophilum symptoms can arise.
Anaplasma phagocytophilum shares its tick vector with other human pathogens, and about 10% of patients with HGA show serologic evidence of coinfection with Lyme disease, babesiosis, or tick-borne meningoencephalitis.
From the first reported case in 1994 until 2010, HGA's rates of incidence have exponentially increased; therefore, it is evolving at a very fast rate. Before 2000, there were less than 300 cases reported per year. In 2000, there were only 350 reported cases. From 2009-2010, HGA experienced a 52% increase in the number of cases reported.
Signs and symptoms
Signs and symptoms may include:
- severe headache
- muscle aches (myalgia)
- chills and shaking, similar to the symptoms of influenza
- loss of appetite
- unintentional weight loss
- abdominal pain
- aching joints
- sensitivity to light
- change in mental status (extreme confusion, memory loss, inability to comprehend environment- interaction, reading, etc.)
- temporary loss of basic motor skills
Symptoms may be minor, as evidenced by surveillance studies in high-risk areas. Gastrointestinal tract symptoms occur in less than half of patients and a skin rash is seen in less than 10% of patients. It is also characterized by a low number of platelets, a low number of white blood cells, and elevated serum transaminase levels in the majority of infected patients. Even though people of any age can get human anaplasmosis, it is usually more severe in the aging or immune-compromised. Some severe complications may include respiratory failure, kidney failure, and secondary infections.
Clinically, HGA is essentially indistinguishable from Human monocytic ehrlichiosis, the infection caused by Ehrlichia chaffeensis, and other tick-borne illnesses such as Lyme disease may be suspected. As Ehrlichia serologies can be negative in the acute period, PCR is very useful for diagnosis.
Treatment and Prevention
Doxycycline is the treatment of choice. If anaplasmosis is suspected, treatment should not be delayed while waiting for a definitive laboratory confirmation, as prompt doxycycline therapy has been shown to improve outcomes. Presentation during early pregnancy can complicate treatment. Doxycycline compromises dental enamel during development. Although rifampin is indicated for post-delivery pediatric and some doxycycline-allergic patients, it is teratogenic. Rifampin is contraindicated during conception and pregnancy. Currently, there is no vaccine against human granulocytic anaplasmosis. If the disease is not treated with antibiotics quickly, sometimes before the diagnosis, the patient has a high chance of mortality. Most patients make a complete recovery, though some patients are intensively cared for after treatment. A reason for a patient needing intensive care is if the patient goes too long without seeing a doctor or being diagnosed. The majority of patients, though, make a 100% recovery with no residual damage.
Although the infectious agent is known to be from the Anaplasma genus, the term "human granulocytic ehrlichiosis" (HGE) is often used, reflecting the prior classification of the organism. E. phagocytophilum and E. equi were reclassified as Anaplasma phagocytophilum.
Major Surface Proteins (MSPs)
Most MSPs are classified as A. marginale and A. phagocytophilum. There are different species of these, because each MSP can only infect certain animals in certain conditions. A. phagocytophilum infects the most, including humans, and all around the world but A. marginale evolved to be more specific in infecting animals, such as deer and cattle in the subtropics and tropics. The main difference between these two MSPs is that the host cell for A. phagocytophilum is the granulocyte, while the host cell for A. marginale is erythrocytes.  It is likely that these MSPs coevolved, because they had previously interacted via tick-pathogen interaction. 
- Human monocytic ehrlichiosis
- Human ewingii ehrlichiosis
- Ehrlichiosis (canine)
- Ticks of domestic animals
- CDC Emerging Infectious Diseases for more information about HGE
- Malik A, Jameel M, Ali S, Mir S (2005). "Human granulocytic anaplasmosis affecting the myocardium". J Gen Intern Med 20 (10): 958. doi:10.1111/j.1525-1497.2005.00218.x. PMC 1490240. PMID 16191146.
- Human Anaplasmosis Basics - Minnesota Dept. of Health
- PMID: Lee HC, Kioi M, Han J, Puri RK, Goodman JL (September 2008). "Anaplasma phagocytophilum-induced gene expression in both human neutrophils and HL-60 cells". Genomics 92 (3): 144–51. doi:10.1016/j.ygeno.2008.05.005. PMID 18603403.
- Bakken, Johan S.; Dumler, J. Stephen (2006-10-01). "Clinical Diagnosis and Treatment of Human Granulocytotropic Anaplasmosis". Annals of the New York Academy of Sciences 1078 (1): 236–247. doi:10.1196/annals.1374.042. ISSN 1749-6632.
- "Human Granulocytic Anaplasmosis and Anaplasma phagocytophilum - Volume 11, Number 12—December 2005 - Emerging Infectious Disease journal - CDC". wwwnc.cdc.gov. Retrieved 2015-10-21.
- Dumler JS, Madigan JE, Pusterla N, Bakken JS (July 2007). "Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment". Clinical Infectious Diseases 45 (Suppl 1): S45–51. doi:10.1086/518146. PMID 17582569.
- "Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis --- United States A Practical Guide for Physicians and Other Health-Care and Public Health Professionals". www.cdc.gov. Retrieved 2015-10-21.
- Massung RF, Courtney JW, Hiratzka SL, Pitzer VE, Smith G, Dryden RL (October 2005). "Anaplasma phagocytophilum in white-tailed deer". Emerging Infectious Diseases 11 (10): 1604–6. doi:10.3201/eid1110.041329. PMID 16318705.
- Dumler JS, Choi KS, Garcia-Garcia JC, et al. (December 2005). "Human granulocytic anaplasmosis and Anaplasma phagocytophilum". Emerging Infectious Diseases 11 (12): 1828–34. doi:10.3201/eid1112.050898. PMC 3367650. PMID 16485466.
- "Statistics | Anaplasmosis | CDC". www.cdc.gov. Retrieved 2015-11-08.
- Murray, Patrick R.; Rosenthal, Ken S.; Pfaller, Michael A. Medical Microbiology, Fifth Edition. United States: Elsevier Mosby, 2005
- Hamburg BJ, Storch GA, Micek ST, Kollef MH (March 2008). "The importance of early treatment with doxycycline in human ehrlichiosis". Medicine 87 (2): 53–60. doi:10.1097/MD.0b013e318168da1d. PMID 18344803.
- Prince LK, Shah AA, Martinez LJ, Moran KA (August 2007). "Ehrlichiosis: making the diagnosis in the acute setting". Southern Medical Journal 100 (8): 825–8. doi:10.1097/smj.0b013e31804aa1ad. PMID 17713310.
- Muffly T, McCormick TC, Cook C, Wall J (2008). "Human granulocytic ehrlichiosis complicating early pregnancy". Infect Dis Obstet Gynecol 2008: 359172. doi:10.1155/2008/359172. PMC 2396214. PMID 18509484.
- Krause PJ, Corrow CL, Bakken JS (September 2003). "Successful treatment of human granulocytic ehrlichiosis in children using rifampin". Pediatrics 112 (3 Pt 1): e252–3. doi:10.1542/peds.112.3.e252. PMID 12949322.
- de la Fuente, José; Kocan, Katherine M.; Blouin, Edmour F.; Zivkovic, Zorica; Naranjo, Victoria; Almazán, Consuelo; Esteves, Eliane; Jongejan, Frans; Daffre, Sirlei (2010-02-10). "Functional genomics and evolution of tick–Anaplasma interactions and vaccine development". Veterinary Parasitology. Ticks and Tick-borne Pathogens 167 (2–4): 175–186. doi:10.1016/j.vetpar.2009.09.019.